Real Medical Services Expenditures by Disease: Neoplasms, MEPS Account Basis (NPSMSMREXMEPS) | FRED | St. Louis Fed
- Rows
- 22
- Columns
- 2
- Data range
- 2000-01-01 to 2021-01-01
Graph and download economic data for Real Medical Services Expenditures by Disease: Neoplasms, MEPS Account Basis (NPSMSMREXMEPS) from 2000 to 2021 about neoplasms, disease, healthcare, medical, health, expenditures, services, real, and USA.
AI analysis
Analysis: Real Medical Services Expenditures by Disease: Neoplasms (MEPS)
1. Dataset Overview and Value
This dataset, sourced from the Federal Reserve Bank of St. Louis (FRED) via the St. Louis Fed's API (fredgraph.csv endpoint), tracks real (inflation-adjusted) medical services expenditures specifically attributable to neoplasms (cancers and tumors) in the United States, drawn from the Medical Expenditure Panel Survey (MEPS) — a nationally representative survey administered by the Agency for Healthcare Research and Quality (AHRQ). FRED's role here is as an aggregator/redistributor of federal statistical data, which lends the series credibility and consistency in formatting, though it also means updates are dependent on MEPS's own release cadence (MEPS data typically lags 2-3 years, consistent with this series ending in 2021). The annual frequency and 22-year span (2000-2021) make this valuable for long-run trend analysis of cancer-related healthcare spending, particularly for studies examining how oncology costs have evolved relative to GDP, insurance coverage expansions (e.g., ACA in 2010), or demographic shifts (aging population).
2. Data Quality Observations
The dataset exhibits excellent completeness: zero null cells across both columns, and all 22 rows have distinct values in both the date and expenditure columns — no duplicate observation dates were found, which is expected and desirable for a clean annual time series. There are no disproportionate-null columns to flag, and no evident type mismatches (dates are properly typed, expenditures are decimal). The one caveat is that duplicate-row recomputation is still pending "Phase D" processing, so a final duplicate check hasn't been fully confirmed, though the distinct-count of 22 matching total rows of 22 is a strong signal of row-level uniqueness already.
3. Key Column Distributions
The core metric, NPSMSMREXMEPS, ranges from a minimum of 97.28 to a maximum of 168.88, indicating roughly a 74% increase in real neoplasm-related medical expenditures over the observed range — a substantial growth trajectory. The mean (136.45) sits close to the median (134.955), and skewness is nearly zero (-0.0912), suggesting a fairly symmetric, non-skewed distribution without significant outlier influence — consistent with a steadily trending time series rather than one with sudden spikes or drops. The interquartile range (Q1=121.475, Q3=151.5) spans about 30 units, reinforcing a gradual, monotonic-like upward trend typical of healthcare cost series rather than volatile or cyclical behavior.
4. Recommended Join Keys
The observationdate column is the clear and only sensible join key, given its annual (year-start, e.g., "2000-01-01") format and zero nulls/full distinctness. For cross-dataset correlation, analysts should align other series to the same annual granularity (Jan 1 timestamps) or aggregate higher-frequency data (monthly/quarterly) to annual averages/sums before joining. Care should be taken to confirm calendar-year vs. fiscal-year alignment when joining with non-FRED datasets.
5. Suggested Complementary Datasets
Strong candidates for correlation analysis include: (a) other MEPS-based disease expenditure series on FRED (e.g., circulatory diseases, mental disorders, diabetes) to compare relative cost growth across conditions; (b) broader healthcare price indices such as the CPI for Medical Care or the PCE Healthcare price index to normalize for inflation-driven vs. utilization-driven cost changes; (c) cancer incidence/mortality data from the CDC or NCI's SEER program to assess whether expenditure growth tracks disease prevalence or reflects treatment cost inflation; (d) health insurance coverage rates (e.g., from the Census Bureau or KFF) to explore whether expanded coverage correlates with expenditure increases; and (e) pharmaceutical R&D spending or oncology drug price indices, since much of neoplasm treatment cost growth is often driven by specialty drug pricing.
Columns
- observation_date (date)
- NPSMSMREXMEPS (decimal)